Expression of microRNA-497 and its prognostic significance in human breast cancer

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Wang, Shaohua ^a   Li, Hanjun ^a   Wang, Jingjie ^a   Wang, Dan ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Breast cancer; Disease free survival; MicroRNA 497; Overall survival; qRT PCR

Indexed keywords

MICRORNA; MIRN497 MICRORNA, HUMAN; TUMOR MARKER;

ARTICLE; BREAST; BREAST TUMOR; COMPARATIVE STUDY; DOWN REGULATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE;

BREAST; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886733085     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-172     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
3. Beckmann MW, Niederacher D, Schnürch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med (Berl) 1997, 75:429-439. 10.1007/s001090050128, 9231883.
4. Ke XS, Liu CM, Liu DP, Liang CC. MicroRNAs: key participants in gene regulatory networks. Curr Opin Chem Biol 2003, 7:516-523. 10.1016/S1367-5931(03)00075-9, 12941428.
5. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531. 10.1038/nrg1379, 15211354.
6. Jovanovic M, Hengartner MO. MiRNAs and apoptosis: RNAs to die for. Oncogene 2006, 25:6176-6187. 10.1038/sj.onc.1209912, 17028597.
7. Listowski MA, Heger E, Bogusławska DM, Machnicka B, Kuliczkowski K, Leluk J, Sikorski AF. MicroRNAs: fine tuning of erythropoiesis. Cell Mol Biol Lett 2013, 18:34-46. 10.2478/s11658-012-0038-z, 23124859.
8. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013, 774:1-20. 10.1007/978-94-007-5590-1_1, 3704221, 23377965.
9. Luzna P, Gregar J, Uberall I, Radova L, Prochazka V, Ehrmann J. Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol 2011, 6:114. 10.1186/1746-1596-6-114, 3268741, 22094011.
10. Mao ZG, He DS, Zhou J, Yao B, Xiao WW, Chen CH, Zhu YH, Wang HJ. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn Pathol 2010, 5:79. 10.1186/1746-1596-5-79, 3017030, 21138567.
11. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007, 6:2127-2132. 10.4161/cc.6.17.4641, 17786041.
12. Profumo V, Gandellini P. MicroRNAs: cobblestones on the road to cancer metastasis. Crit Rev Oncog 2013, 18:341-355. 10.1615/CritRevOncog.2013007182, 23614620.
13. Landskroner-Eiger S, Moneke I, Sessa WC. MiRNAs as modulators of angiogenesis. Cold Spring Harb Perspect Med 2013, 3:a006643.
14. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
15. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007, 8:R214. 10.1186/gb-2007-8-10-r214, 2246288, 17922911.
16. Lerebours F, Cizeron-Clairac G, Susini A, Vacher S, Mouret-Fourme E, Belichard C, Brain E, Alberini JL, Spyratos F, Lidereau R, Bieche I. MiRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness. Int J Cancer 2013, 133:1614-1623. 10.1002/ijc.28171, 23526361.
17. Luo M, Shen D, Zhou X, Chen X, Wang W. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery 2013, 153:836-847. 10.1016/j.surg.2012.12.004, 23453369.
18. Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, Thorne RF, Jin L, Zhang XD. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2013, 32:1910-1920. 10.1038/onc.2012.214, 3630484, 22710713.
19. Wang L, Li B, Li L, Wang T. MicroRNA-497 suppresses proliferation and induces apoptosis in prostate cancer cells. Asian Pac J Cancer Prev 2013, 14:3499-3502.
20. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360. 10.1261/rna.1034808, 2578865, 18812439.
21. Shen L, Li J, Xu L, Ma J, Li H, Xiao X, Zhao J, Fang L. MiR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med 2012, 3:475-480. 3438749, 22969914.
22. Muyal JP, Muyal V, Kaistha BP, Seifart C, Fehrenbach H. Systematic comparison of RNA extraction techniques from frozen and fresh lung tissues: checkpoint towards gene expression studies. Diagn Pathol 2009, 4:9. 10.1186/1746-1596-4-9, 2669047, 19317905.
23. Cho WC. Great potential of miRNAs as predictive and prognostic markers for cancer. Expert Rev Mol Diagn 2012, 12:315-318. 10.1586/erm.12.21, 22616694.
24. Elledge RM, McGuire WL, Osborne CK. Prognostic factors in breast cancer. Semin Oncol 1992, 19:244-253.
25. Hayes DF. Tumor markers for breast cancer. Ann Oncol 1993, 4:807-819.
26. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005, 4:1179-1184. 10.4161/cc.4.9.2032, 16096373.
27. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013, 329:125-136. 10.1016/j.canlet.2012.11.001, 23196059.
28. Anindo MI, Yaqinuddin A. Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg 2012, 10:443-449. 10.1016/j.ijsu.2012.08.006, 22906693.
29. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 2010, 17:R245-R262. 10.1677/ERC-10-0136, 20647302.
30. Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev 2009, 35:328-334. 10.1016/j.ctrv.2008.12.002, 19171434.
31. Tang W, Zhu J, Su S, Wu W, Liu Q, Su F, Yu F. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One 2012, 7:e51702. 10.1371/journal.pone.0051702, 3519894, 23240057.
32. Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene 2012, 507:135-168. 10.1016/j.gene.2012.07.025, 22842193.
33. Zhou X, Marian C, Makambi KH, Kosti O, Kallakury BV, Loffredo CA, Zheng YL. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One 2012, 7:e39011. 10.1371/journal.pone.0039011, 3377597, 22723919.
34. Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res 2012, 195:151-161. 10.1007/978-3-642-28160-0_13, 22527502.
35. Criscitiello C, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer. Curr Opin Oncol 2010, 22:552-558. 10.1097/CCO.0b013e32833de186, 20706122.
36. Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA, Wang B, Lu MY, Pan CK, Chen P. Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem Biophys Res Commun 2013, 435:466-471. 10.1016/j.bbrc.2013.05.010, 23673296.
37. Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S, Inazawa J. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One 2013, 8:e60155. 10.1371/journal.pone.0060155, 3609788, 23544130.
38. Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, Stallings RL. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer 2013, 12:23. 10.1186/1476-4598-12-23, 3626575, 23531080.
39. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, Shu Y, Liu P. MiR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012, 29:384-391. 10.1007/s12032-010-9797-4, 21258880.
40. Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, Schipper E, Hille U, Kreipe HH, Länger F. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 2010, 10:109. 10.1186/1471-2407-10-109, 2850898, 20331864.
41. Seccareccia E, Brodt P. The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Horm IGF Res 2012, 22:193-199. 10.1016/j.ghir.2012.09.003, 23098677.
42. Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:485-498. 10.1007/s10911-008-9107-3, 19034632.
43. Goldmann T, Burgemeister R, Sauer U, Loeschke S, Lang DS, Branscheid D, Zabel P, Vollmer E. Enhanced molecular analyses by combination of the HOPE-technique and laser microdissection. Diagn Pathol 2006, 1:2. 10.1186/1746-1596-1-2, 1501060, 16759346.